• SearchField_GetLegal

Cylert

CylertCylert is the brand name for Pemoline, a stimulant first synthesized in 1913 and used to treat ADHD (attention deficit hyperactivity disorder) and narcolepsy. Pemoline has been pulled from the U.S. market because of reports connecting its use in children to increased risk of liver failure. After the U.S. Food and Drug Administration (FDA) issued a warning not to prescribe Pemoline for ADHD, the manufacturer and patent owner (Abbott Laboratories) stopped making Cylert.

Pemoline was first approved by the FDA in 1975. Since that date, more than 20 liver failures have been linked to the drug. Pemoline is believed to cause hepatoxicity, a chemically induced form of liver damage.

If you or someone you love has used any type of Cylert and experienced detrimental side effects, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

    Latest Article

      GETLEGAL®ATTORNEY DIRECTORY

      Find Leading Attorneys in Your Area

          NEED PROFESSIONAL HELP?

          Talk to an Attorney

          How It Works

          • Briefly tell us about your case
          • Provide your contact information
          • Choose attorneys to contact you
          • SearchField_GetLegal

          ABOUT GETLEGAL

          Our mission at GetLegal is to develop a family of sites that constitute the most useful, informative, reliable and exciting collection of legal resources on the web. We are constantly working to expand and improve many resources we offer to legal professionals and the public.

          Contact Us : 877-359-7077

          RECENT TWEETS

          NEWSLETTER SIGN-UP

          By submitting information to this site, you give permission to GetLegal, or a partner of GetLegal, to contact you by email.

          Advertise With Us

          © 2008-2021 LawConnect, Inc. All rights reserved. Sitemap | Copyright/DMCA Policy | Privacy Policy | Terms of Use | Disclosures/Disclaimers